[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
NCT ID: NCT06120049
Last Updated: 2025-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
113 participants
INTERVENTIONAL
2024-01-19
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this prospective head to head comparison is to evaluate the effectiveness of \[18F\]-MFBG PET in assessing cardiac innervation, comparing it with \[123I\]-MIBG SPECT The study's primary focus is on distinguishing between Parkinson's disease (PD) and multiple system atrophy (MSA), as well as between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD).
Main questions:
* Feasibility: How well can \[18F\]-MFBG PET detect changes in myocardial uptake in PD and DLB compared to the expected normal values in healthy individuals and AD and MSA-P patients? How well can it differentiate between these groups based on the detected changes?
* Non-inferiority: Is \[18F\]-MFBG PET as accurate as \[123I\]-MIBG SPECT in distinguishing between PD and MSA-P, and between DLB and AD?
Participant requirements:
For the main study, participants will be required to visit the hospital for 3 or 4 appointments. During these visits, they will undergo a screening visit, MRI brain scan, a comprehensive neurological assessment, \[18F\]-PE2I PET, \[123I\]-MIBG SPECT, and \[18F\]-MFBG PET scans.
Additionally, a separate dosimetry study will be conducted, involving healthy subjects who will visit the hospital for a screening visit and undergo \[18F\]-MFBG PET scans.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI)
NCT00820937
Synaptic Density, Tau and Multiparametric PET-MR in Brain Trauma, Stroke and Mild Cognitive or Behavioral Impairment.
NCT03514524
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
NCT04150198
Early Detection of Mild Cognitive Impairment in Individual Patients
NCT00243451
Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging
NCT01815112
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This prospective study, to be conducted in two centers (UZ Leuven and UZ Gent), aims to validate cardiac \[18F\]-MFBG PET in distinguishing Parkinson's disease (PD) from multiple system atrophy (MSA-P) and differentiating dementia with Lewy bodies (DLB) from Alzheimer's disease (AD). Both PD and DLB, caused by alpha-synuclein deposits (Lewy bodies), exhibit not only nigrostriatal dopaminergic deficits but also early peripheral changes in myocardial norepinephrine (NE) innervation. These defects can be visualized and quantified using NE transporter tracers. \[18F\]-MFBG was developed several years ago with high-yield production and has already been employed in multiple centers worldwide, mainly in the context of imaging neuroendocrine tumors. \[18F\]-MFBG offers logistical, technical, and pharmacological advantages, including faster scanning, high spatial resolution, and improved quantification compared to the existing method using \[123I\]-MIBG SPECT.
Participant Population:
The study will include 28 healthy volunteers (CON), of which 3 will participate in \[18F\]-MFBG PET dosimetry (part 1) and 25 in the main study for optimization/age-dependence of cardiac \[18F\]-MFBG parameters (part 2). In part 3, 40 PD, 15 MSA-P, 15 DLB, and 15 AD patients with biomarker-confirmed diagnoses will be included. Total: 113 subjects.
Intervention:
All subjects will undergo three examinations in the main work packages (parts 2 and 3) dynamic cardiac \[18F\]-MFBG PET, with dynamic \[123I\]-MIBG SPECT as a comparator, as well as cerebral \[18F\]-PE2I PET.
Endpoints:
Primary: Non-inferiority in discriminating populations using \[18F\]-MFBG; Secondary: effect size, relationship between myocardial uptake and cerebral dopamine active transporter (DAT) changes, autonomic dysfunction, regional myocardial variation.
Secondary:
1. Determine the effect size (ES) of the reduction in myocardial uptake of \[18F\]-MFBG in PD and DLB compared to \[123I\]-MIBG SPECT and \[123I\]-MIBG planar scintigraphy.
2. Identify any significant correlation between the reduction in myocardial uptake of \[18F\]-MFBG in PD and DLB and the reduction in \[18F\]-PE2I binding in early to moderate disease stages.
3. Assess the relationship between the reduction in myocardial uptake of \[18F\]-MFBG in PD and DLB and measures of autonomic dysfunction.
4. Examine the regional pattern of reduced \[18F\]-MFBG uptake in PD/DLB compared to controls, with an endpoint considered met if different regional segment scores are evident between PD/MSA-P or DLB/AD or subtypes of PD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy controls (part 2)
25 healthy subjects (5 young 20-40y and 20 between 50-85y) will be enrolled for the head-to-head comparison with \[18F\]-MFBG, \[123I\]-MIBG and \[18F\]-FE-PE2I (Part 2).
In 5 healthy controls, arterial sampling will be carried out for kinetic modelling.
[18F]-MFBG PET CT
\[18F\]-MFBG will be acquired at the Leuven University hospital on a GE MI4 PET/CT camera, with low dose CT and 120 MBq injected activity. Dynamic imaging between 0-60 minutes and 100-120 minutes (patients) and 0-70 minutes and 90-120 minutes (healthy volunteers).
Venous sampling between 5-120 minutes will be obtained through a second catheter, 6 venous samples will be taken.
In healthy up to 5 control subjects, full arterial sampling (0-120 minutes,) will also be done.
If patient comfort allows, after the dynamic cardiac scan 2 hours post-injection field dynamic scan, a fast late timepoint whole body PET/CT will be taken (2 min/bed position, 11 mAs low dose CT; estimated 10-12 minutes).
[18F]-FE-PE2I PET CT or PET MRI
\[18F\]-FE-PE2I will be performed at the University Hospital Leuven with the GE Signa simultaneous PET/MR with acquisition at 50-70 minutes postinjection or at the University Hospital in Gent using a Siemens PET/CT, GE MI4 PET/CT.
Injected activity: 120 MBq
[123I]-MIBG SPECT CT
\[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.
Injected activity: 111 MBq
PD vs MSA cohort (part 3a)
In total, 40 PD patients will be included. In order to determine relationships with disease progression, two subgroups will be included with disease duration up to 5 years and 5 years or more respectively. In total, 15 MSA-P patients will be enrolled. For both groups, abnormal previous \[18F\]-FE-PE2I or \[123I\]-FP-CIT SPECT scan is required.
Head-to-head comparison with \[18F\]-MFBG, \[123I\]-MIBG and \[18F\]-FE-PE2I (Part 3).
[18F]-MFBG PET CT
\[18F\]-MFBG will be acquired at the Leuven University hospital on a GE MI4 PET/CT camera, with low dose CT and 120 MBq injected activity. Dynamic imaging between 0-60 minutes and 100-120 minutes (patients) and 0-70 minutes and 90-120 minutes (healthy volunteers).
Venous sampling between 5-120 minutes will be obtained through a second catheter, 6 venous samples will be taken.
In healthy up to 5 control subjects, full arterial sampling (0-120 minutes,) will also be done.
If patient comfort allows, after the dynamic cardiac scan 2 hours post-injection field dynamic scan, a fast late timepoint whole body PET/CT will be taken (2 min/bed position, 11 mAs low dose CT; estimated 10-12 minutes).
[18F]-FE-PE2I PET CT or PET MRI
\[18F\]-FE-PE2I will be performed at the University Hospital Leuven with the GE Signa simultaneous PET/MR with acquisition at 50-70 minutes postinjection or at the University Hospital in Gent using a Siemens PET/CT, GE MI4 PET/CT.
Injected activity: 120 MBq
[123I]-MIBG SPECT CT
\[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.
Injected activity: 111 MBq
AD vs DLB cohort (part 3b)
In total 15 patients with probable DLB (including biomarker selection through abnormal previous \[18F\]-FE-PE2I or \[123I\]-FP-CIT SPECT scan) and 15 patients with probable AD (including biomarker proven amyloid-beta positivity either by cerebrospinal fluid biomarker analysis or by \[18F\]-NAV4694 imaging as standard of care).
Head-to-head comparison with \[18F\]-MFBG, \[123I\]-MIBG and \[18F\]-FE-PE2I (Part 3).
[18F]-MFBG PET CT
\[18F\]-MFBG will be acquired at the Leuven University hospital on a GE MI4 PET/CT camera, with low dose CT and 120 MBq injected activity. Dynamic imaging between 0-60 minutes and 100-120 minutes (patients) and 0-70 minutes and 90-120 minutes (healthy volunteers).
Venous sampling between 5-120 minutes will be obtained through a second catheter, 6 venous samples will be taken.
In healthy up to 5 control subjects, full arterial sampling (0-120 minutes,) will also be done.
If patient comfort allows, after the dynamic cardiac scan 2 hours post-injection field dynamic scan, a fast late timepoint whole body PET/CT will be taken (2 min/bed position, 11 mAs low dose CT; estimated 10-12 minutes).
[18F]-FE-PE2I PET CT or PET MRI
\[18F\]-FE-PE2I will be performed at the University Hospital Leuven with the GE Signa simultaneous PET/MR with acquisition at 50-70 minutes postinjection or at the University Hospital in Gent using a Siemens PET/CT, GE MI4 PET/CT.
Injected activity: 120 MBq
[123I]-MIBG SPECT CT
\[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.
Injected activity: 111 MBq
Dosimetry in healthy controls (Part 1)
For dosimetry of \[18F\]-MFBG only, 3 subjects (18-80 y) will be enrolled (Part 1).
[18F]-MFBG PET dosimetry scans
\[18F\]-MFBG will be acquired at the Leuven University hospital on a Siemens Truepoint or GE MI4 PET/CT camera or equivalent newer camera, with low dose CT and 120 MBq injected activity.
Three segments of consecutive whole-body scanning with increasing bed position duration will be carried out up to 3 half-lives (physical half-life T1/2 for 18F = 110 minutes): from 0-90 minutes (scan 1-8), 120-150 (scan 9) and 300-330 (scan 10) minutes post injection. In total 10 whole body biodistribution scans will be taken. Urine will be collected and its total activity measured to measure bladder excretion for correction of integrated bladder organ residence. Before each segment, a low dose whole body CT scan (11 mAs) will be acquired for attenuation correction and organ delineation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[18F]-MFBG PET CT
\[18F\]-MFBG will be acquired at the Leuven University hospital on a GE MI4 PET/CT camera, with low dose CT and 120 MBq injected activity. Dynamic imaging between 0-60 minutes and 100-120 minutes (patients) and 0-70 minutes and 90-120 minutes (healthy volunteers).
Venous sampling between 5-120 minutes will be obtained through a second catheter, 6 venous samples will be taken.
In healthy up to 5 control subjects, full arterial sampling (0-120 minutes,) will also be done.
If patient comfort allows, after the dynamic cardiac scan 2 hours post-injection field dynamic scan, a fast late timepoint whole body PET/CT will be taken (2 min/bed position, 11 mAs low dose CT; estimated 10-12 minutes).
[18F]-FE-PE2I PET CT or PET MRI
\[18F\]-FE-PE2I will be performed at the University Hospital Leuven with the GE Signa simultaneous PET/MR with acquisition at 50-70 minutes postinjection or at the University Hospital in Gent using a Siemens PET/CT, GE MI4 PET/CT.
Injected activity: 120 MBq
[123I]-MIBG SPECT CT
\[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.
Injected activity: 111 MBq
[18F]-MFBG PET dosimetry scans
\[18F\]-MFBG will be acquired at the Leuven University hospital on a Siemens Truepoint or GE MI4 PET/CT camera or equivalent newer camera, with low dose CT and 120 MBq injected activity.
Three segments of consecutive whole-body scanning with increasing bed position duration will be carried out up to 3 half-lives (physical half-life T1/2 for 18F = 110 minutes): from 0-90 minutes (scan 1-8), 120-150 (scan 9) and 300-330 (scan 10) minutes post injection. In total 10 whole body biodistribution scans will be taken. Urine will be collected and its total activity measured to measure bladder excretion for correction of integrated bladder organ residence. Before each segment, a low dose whole body CT scan (11 mAs) will be acquired for attenuation correction and organ delineation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Voluntary written informed consent.
* Use of highly effective methods of birth control.
* Age between 18 and 85 years.
* Good health based on medical history, physical examination, clinical laboratory tests, and urinalysis.
* No history or evidence of major neurological, internal, or psychiatric disorders.
* Normal structural MRI scan for subjects \< 60 years or minor lesions for subjects \>= 60 years.
2. Parkinson's Disease:
* Age 45-85 years.
* Clinically established PD based on Movements Disorder Society diagnostic criteria.
* Disease duration since onset of motor symptoms: 5 years or longer for one group and less than 5 years for another.
* Previous abnormal \[18F\]-FE-PE2I PET or \[123I\]-FP-CIT SPECT scan.
* Ability to understand the patient information brochure and provide written informed consent.
3. Multiple System Atrophy - Parkinsonian Variant:
* Age 45-85 years.
* Clinically established or clinically probable MSA-P based on MDS diagnostic criteria.
* Previous abnormal \[18F\]-FE-PE2I PET or \[123I\]-FP-CIT SPECT scan.
* Ability to understand the patient information brochure and provide written informed consent.
4. Dementia Due to Alzheimer's Disease:
* Age 50-85 years.
* Diagnosis of probable AD with evidence of the AD pathophysiological process.
* Ability to understand the patient information brochure and provide written informed consent.
5. Dementia with Lewy Bodies:
* Age 50-85 years.
* Diagnosis of probable DLB.
* Previous abnormal \[18F\]-FE-PE2I PET or \[123I\]-FP-CIT SPECT scan.
* Ability to understand the patient information brochure and provide written informed consent.
Exclusion Criteria
* Major diseases that may interfere with the investigations.
* Evidence of cognitive impairment.
* History or evidence of psychiatric disease.
* Use of illicit drugs or history of drug or alcohol abuse.
* Chronic medication interfering with cardiac neuronal norepinephrine transporter (NET) or \[18F\]-FE-PE2I imaging.
* Exposure to ionizing radiation \> 1 mSv in other research studies within the last 12 months.
* Contraindication for MRI scanning.
* Claustrophobia or inability to tolerate confinement during PET-MRI scanning.
* Unwillingness to avoid strenuous physical activity.
* Lack of understanding of the study procedures.
* Pregnancy or breastfeeding.
* Lack of agreement to communicate incidental findings to the general practitioner.
* Abnormal Allen test or lidocaine hypersensitivity/allergy for subjects willing to undergo arterial sampling.
2. Parkinson's Disease:
* Neuropsychiatric diseases other than PD.
* Major internal medical comorbidity, especially diabetes or heart disease.
* White matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI abnormalities.
* History of alcohol or drug abuse.
* Previous participation in research studies involving ionizing radiation.
* Contraindications for MR.
* Claustrophobia or inability to tolerate confinement during PET scanning.
* Unwillingness to avoid strenuous physical activity.
* Lack of understanding of the study procedures.
* Pregnancy or breastfeeding.
* Lack of agreement to communicate incidental findings to the general practitioner.
* Anticoagulant therapy.
3. Multiple System Atrophy - Parkinsonian Variant:
* Same as for Parkinson's disease.
4. Dementia Due to Alzheimer's Disease:
* Same as for Parkinson's disease.
5. Dementia with Lewy Bodies:
* Same as for Parkinson's disease.
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Ghent
OTHER
Fund for Scientific Research, Flanders, Belgium
OTHER
KU Leuven
OTHER
Universitaire Ziekenhuizen KU Leuven
OTHER
prof. dr. Koen Van Laere
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
prof. dr. Koen Van Laere
Head of Nuclear Medicine, professor, Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Koen Van Laere
Role: PRINCIPAL_INVESTIGATOR
Professor at KULeuven, department head of nuclear medicine at UZ Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UZ Ghent
Ghent, Gent, Belgium
UZ Leuven
Leuven, Vlaams-Brabant, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Versweyveld L, Delva A, Cohilis M, Deroose CM, Van Weehaeghe D, Koole M, Vandenberghe W, Van Laere K. [18F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson's disease: dosimetry and pharmacokinetics. Eur J Nucl Med Mol Imaging. 2025 Sep 9. doi: 10.1007/s00259-025-07517-3. Online ahead of print.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S67620
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.